[go: up one dir, main page]

ATE408828T1 - Verfahren zur erkennung eines ovarialkarzinoms - Google Patents

Verfahren zur erkennung eines ovarialkarzinoms

Info

Publication number
ATE408828T1
ATE408828T1 AT06735360T AT06735360T ATE408828T1 AT E408828 T1 ATE408828 T1 AT E408828T1 AT 06735360 T AT06735360 T AT 06735360T AT 06735360 T AT06735360 T AT 06735360T AT E408828 T1 ATE408828 T1 AT E408828T1
Authority
AT
Austria
Prior art keywords
detecting
ovarial carcinoma
ovarial
carcinoma
biomarkers
Prior art date
Application number
AT06735360T
Other languages
English (en)
Inventor
David Livingston
Ronny Drapkin
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE408828T1 publication Critical patent/ATE408828T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AT06735360T 2005-02-16 2006-02-16 Verfahren zur erkennung eines ovarialkarzinoms ATE408828T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65341005P 2005-02-16 2005-02-16

Publications (1)

Publication Number Publication Date
ATE408828T1 true ATE408828T1 (de) 2008-10-15

Family

ID=36694431

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06735360T ATE408828T1 (de) 2005-02-16 2006-02-16 Verfahren zur erkennung eines ovarialkarzinoms

Country Status (6)

Country Link
US (1) US8486648B2 (de)
EP (1) EP1859273B1 (de)
AT (1) ATE408828T1 (de)
CA (1) CA2597271A1 (de)
DE (1) DE602006002809D1 (de)
WO (1) WO2006089125A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
WO2006119155A2 (en) * 2005-05-02 2006-11-09 The Brigham And Women's Hospital, Inc. Diagnostic serum antibody profiling
JP5221381B2 (ja) * 2006-01-04 2013-06-26 フジレビオ アメリカ、インク． 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用
WO2007081386A2 (en) 2006-01-11 2007-07-19 Raindance Technologies, Inc. Microfluidic devices and methods of use
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP4190448A3 (de) 2006-05-11 2023-09-20 Bio-Rad Laboratories, Inc. Mikrofluidische vorrichtungen
EP3536396B1 (de) 2006-08-07 2022-03-30 The President and Fellows of Harvard College Fluorkohlenstoffemulsionsstabilisierende tenside
US8329399B2 (en) * 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
JP2010520768A (ja) 2007-03-09 2010-06-17 トライパス イメージング インコーポレイテッド Ｈｅ４モノクローナル抗体およびそれらの使用方法
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
JP2010531991A (ja) * 2007-07-02 2010-09-30 ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・エディンバラ 異所性妊娠の同定
WO2009099561A2 (en) * 2008-01-31 2009-08-13 The Brigham And Womens' Hospital, Inc. Urinary ca125 peptides as biomarkers of ovarian cancer
WO2009145815A2 (en) * 2008-04-01 2009-12-03 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
EP4047367A1 (de) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Verfahren zum nachweis von zielanalyten unter verwendung von tropfenbibliotheken
WO2010111231A1 (en) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation of microfluidic droplets
EP2486409A1 (de) 2009-10-09 2012-08-15 Universite De Strasbourg Markiertes nanomaterial auf siliziumbasis mit verbesserten eigenschaften und seine verwendung
WO2011079176A2 (en) 2009-12-23 2011-06-30 Raindance Technologies, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
US20120295814A1 (en) * 2010-01-08 2012-11-22 The Brigham And Women's Hospital, Inc. CA-125 Immune Complexes as Biomarkers of Ovarian Cancer
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
EP2534267B1 (de) 2010-02-12 2018-04-11 Raindance Technologies, Inc. Digitale analyse von analyten
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
EP3447155A1 (de) 2010-09-30 2019-02-27 Raindance Technologies, Inc. Sandwichassays in tröpfchen
EP3859011A1 (de) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Verfahren zur bildung gemischter tröpfchen
KR101854110B1 (ko) 2011-02-17 2018-05-04 후지레비오 다이어그노스틱스, 인코포레이티드 ＨＥ4ａ의 결정을 위해 사용되는 조성물들 및 방법들
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
EP3216872B1 (de) 2011-06-02 2020-04-01 Bio-Rad Laboratories, Inc. Enzymquantifizierung
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
EP3524693A1 (de) 2012-04-30 2019-08-14 Raindance Technologies, Inc. Digitale analytanalyse
EP2986762B1 (de) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digitale analyse von analyten
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
EP3482205A1 (de) 2016-07-08 2019-05-15 H. Hoffnabb-La Roche Ag Verwendung des humanen epididymisproteins 4 (he4) zur beurteilung des ansprechens auf eine behandlung von muc-16-positivem krebs
US11360092B2 (en) 2016-08-05 2022-06-14 The Research Foundation For The State University Of New York Keratin 17 as a biomarker for bladder cancer
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
KR102260999B1 (ko) 2019-03-27 2021-06-04 (주)엠케어코리아 난소암 검사용 임플란트 및 이를 포함하는 검사킷 및 이를 이용한 난소암 검사방법
KR102570635B1 (ko) 2020-11-23 2023-08-25 서울대학교병원 샘플링 장치

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230767A (en) 1978-02-08 1980-10-28 Toyo Boseki Kabushiki Kaisha Heat sealable laminated propylene polymer packaging material
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
WO2003033731A2 (en) * 2001-10-16 2003-04-24 Mount Sinai Hospital Methods for detecting ovarian cancer

Also Published As

Publication number Publication date
EP1859273A2 (de) 2007-11-28
DE602006002809D1 (de) 2008-10-30
US20080286199A1 (en) 2008-11-20
US8486648B2 (en) 2013-07-16
WO2006089125A2 (en) 2006-08-24
WO2006089125A3 (en) 2006-12-21
CA2597271A1 (en) 2006-08-24
EP1859273B1 (de) 2008-09-17

Similar Documents

Publication Publication Date Title
ATE408828T1 (de) Verfahren zur erkennung eines ovarialkarzinoms
IN2013CN01129A (de)
EP1869462A4 (de) Biomarker für ovarialkrebs und endometriumkrebs: hepcidin
MX340453B (es) Biomarcadores para cancer de pulmon.
PH12013502230A1 (en) Multispecific antibodies
IL287261A (en) Compounds and methods for detecting analytes using bioluminescence
WO2010009337A3 (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
ATE483972T1 (de) Reagenzien und verfahren für krebsprognose und pathologische einstufung
EA201300654A1 (ru) Детектирование событий получения трансгенных растений
EA201190210A1 (ru) Ингибиторы связывания киназы с белком
EP2082065A4 (de) Prognostisches multigen-testverfahren für lungenkrebs
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
DE112006001755A5 (de) EU/TB-Chelat-basiertes fluoreszenzspektroskopisches Verfahren zum Nachweis von Analyten
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
EA201791578A1 (ru) Панель биомаркеров для обнаружения рака
EP2074422A4 (de) Verfahren und kits für den nachweis von prostatakrebs-biomarkern
NI201100106A (es) Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y vincristina.
WO2012021887A3 (en) Biomarkers for the early detection of breast cancer
DK2211180T3 (da) Anvendelse af protein SATB2 som markør til at skelne colorectal cancer fra andre former for cancer
DK2002016T3 (da) Fremgangsmåde til bestemmelse af kopital
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
EP2831281A4 (de) Molekulare marker zur prognostischen vorhersage von prostatakrebs, verfahren und kit dafür
DE602006005084D1 (de) Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen
EP1862804A4 (de) Verfahren zur diagnose von prostatakrebs
WO2010009074A3 (en) Method for predicting and detecting tumor metastasis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
REN Ceased due to non-payment of the annual fee